For more information, visit our Gynecological Cancer Program
Return to Cancer Program Name Search
Title: Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors
Brief Title: REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Brief Summary: The purpose of this study is to see whether a supportive intervention (REVITALIZE)
reduces fatigue and its impact on daily life and activities for participants with ovarian
cancer taking PARP inhibitors.
The name of the study groups in this research study are:
1. REVITALIZE
2. Educational Materials
For info regarding 24-105
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: A phase 2 trial of maintenance abemaciclib/letrozole after systemic therapy in patients with advanced or recurrent estrogen receptor positive, mismatch repair proficient, TP53 wild-type endometrial cancer
Brief Title: ALPINE: Maintenance Letrozole/Abemaciclib
Brief Summary: The purpose of this research study is to see if the study drugs abemaciclib and letrozole
are effective and safe for participants with estrogen-receptor positive (ER+), mismatch
repair proficient, tumor protein p53 (TP53) wild-type endometrial cancer.
The names of the study drugs involved in this study are:
- Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor)
- Letrozole (a type of aromatase inhibitor)
For info regarding 23-695
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib alone and in Combination with Metformin, Zotatifin and Gedatolisib
Brief Title: RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Brief Summary: This research study is studying a combination of targeted therapies as a possible
treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous
ovarian cancer.
The drugs involved in this study are:
- Abemaciclib (also known as Verzenio™)
- Letrozole (also known as Femara®)
- Metformin (also known as Glucophage®)
- Zotatifin (also known as eFT226)
- Gedatolisib (also known as PF-05212384)
For info regarding 18-301
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Identification of Molecular Alterations Required in the Development of Ovarian Carcinomas
Brief Title: IDENTIFICATION OF MOLECULAR ALTERATIONS REQUIRED IN THE DEVELOPMENT OF OVARIAN CARCINOMAS
For info regarding 14-132
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu